The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
April 29 (Reuters) - AbbVie (ABBV.N), opens new tab on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and Rinvoq, as it ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective therapies from AbbVie and Grace Therapeutics. For AbbVie, the Chicago drugmaker had ...
After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more definitive step into the red-hot cancer field. The Chicago pharma has agreed to ...
Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology megablockbuster Humira, CEO Robert Michael can now declare that “we have never been in a ...
AbbVie (ABBV) shares added ~2% in the premarket on Thursday after the company raised its full-year earnings outlook as its newer immunology drugs, Skyrizi and Rinvoq, offset weakness in its former ...
It will be important to monitor the performance of AbbVie's main growth drivers in the first quarter. Some of the drugmaker's other products might not perform well. AbbVie's underlying business and ...
Our fair value estimate would rise significantly if we could gain confidence in AbbVie’s ability to grow in the final years of our 10-year explicit forecast. AbbVie ABBV reported 12% revenue and 8% ...
A major Triangle investment in new life sciences space may be the icing on the cake for a resurgent biotech sector in North Carolina. Illinois-based AbbVie announced last week it would spend $1.4B for ...
Good morning, and thank you for standing by. Welcome to the AbbVie First Quarter 2026 Earnings Conference Call. [Operator Instructions] Today's call is also being recorded. If you have any objections, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results